News

Marketing Authorization Application for lecanemab as treatment for early Alzheimer’s disease filed in South Korea

by

STOCKHOLM, June 8, 2023 /PRNewswire/ — BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that Eisai has submitted a marketing authorization application for lecanemab (brand name in the U.S.: LEQEMBI™), an investigational anti-amyloid beta (Aβ) protofibril[1] antibody, for the treatment of early Alzheimer’s disease[2] with confirmed amyloid pathology in the brain, to the Ministry of … Read more

Major Players Include Elliot Scientific, Shanghai Laser & Optics Century, GenSight Biologics and Danaher

by

DUBLIN, June 7, 2023 /PRNewswire/ — The “Optogenetics Global Market Report 2023” report has been added to  ResearchAndMarkets.com’s offering. This report provides strategists, marketers and senior management with the critical information they need to assess the market. The global optogenetics market is expected to grow from $28.15 billion in 2022 to $32.26 billion in 2023 … Read more

Increasing Prevalence of Cancer and Metabolic Disorders Drives Growth

by

DUBLIN, June 7, 2023 /PRNewswire/ — The “Peptide Therapeutics Market – Growth, Trends, COVID-19 Impact and Forecasts (2023-2028)” report has been added to  ResearchAndMarkets.com’s offering. The peptide therapeutics market is expected to register a CAGR of 9.66% over the forecast period. Companies Mentioned Eli Lilly and Company Amgen Inc. Pfizer Inc. Bristol-Myers Squibb Company Ever … Read more

Increasing Prevalence of Neonatal Pulmonary Hypertension and Acute Respiratory Distress Syndrome Drives Growth

by

DUBLIN, June 7, 2023 /PRNewswire/ — The “Nitric Oxide Therapy Systems Market: Global Market Size, Forecast, Insights, and Competitive Landscape” report has been added to  ResearchAndMarkets.com’s offering. The global nitric oxide therapy system market is expected to grow at a CAGR of around 4.1% during 2023-2030. Companies Mentioned Bellerophon Therapeutics BOC Healthcare Dan Hammer Health … Read more

Auna S.A.A. Announces Expiration and Receipt of Requisite Consents with Respect to Consent Solicitation for Senior Notes due 2025

by

MEXICO CITY and LIMA, Peru, June 7, 2023 /PRNewswire/ — Auna S.A.A. (“Auna” or the “Company“) announced today the expiration of its previously announced solicitation (the “Consent Solicitation“) of consents (the “Consents“) and receipt of the requisite Consents from holders (the “Holders“) of Auna’s outstanding 6.500% Senior Notes due 2025 (the “Notes“) to effect a … Read more

BoomerangFX Partners with DrFirst to Launch E-Prescribing for Aesthetic Medicine Practices Across North America

by

Partnership delivers first fully integrated solution that allows physicians to prescribe and manage patients’ medications while simultaneously utilizing Charting, EMR, Scheduling, Lead Management, CRM, Point-of-Sale Payments, Inventory Management and Accounting Reports. TORONTO and MIAMI, June 7, 2023 /PRNewswire/ – BoomerangFX, an international cloud-based SaaS provider of end-to-end practice management solutions for non-insured, private-pay healthcare segments … Read more

Expanding Role of Outsourcing Partners and Rising Demand for Full-Service Providers

by

DUBLIN, June 7, 2023 /PRNewswire/ — The “Medical Device Outsourcing: Global Strategic Business Report” report has been added to  ResearchAndMarkets.com’s offering. Global Medical Device Outsourcing Market to Reach $212.1 Billion by 2030 In the changed post COVID-19 business landscape, the global market for Medical Device Outsourcing estimated at US$105.2 Billion in the year 2022, is … Read more

MemorialCare Long Beach Medical Center’s Family Medicine Residency Program Celebrates 50th Anniversary

by

Training the next generation of physicians brings new clinical pathways, ideas, and collaboration to shape the future of healthcare in the greater Long Beach community. LONG BEACH, Calif., June 7, 2023 /PRNewswire/ — The Family Medicine Residency Program at MemorialCare Long Beach Medical Center and Miller Children’s & Women’s Hospital Long Beach is celebrating its … Read more

U.S. Immunology Treaters Resistant to Switching Stable Humira Patients to Biosimilars, According to Spherix Global Insights

by

Adalimumab biosimilars hold potential to grow the overall biologic-treated population, but only if the cost savings translate to patients and practices. EXTON, Pa., June 7, 2023 /PRNewswire/ — Amgen launched the first U.S. adalimumab biosimilar, Amjevita, in January 2023. Yet according to the latest findings from Spherix Global Insights, even the first to market advantage can’t … Read more